6,322 Shares in QIAGEN N.V. $QGEN Purchased by Callan Family Office LLC

Key Points

• Callan Family Office LLC has acquired 6,322 shares of QIAGEN N.V. valued at approximately $304,000, reflecting growing institutional interest in the company.
• QIAGEN reported earnings of $0.60 per share for the last quarter, which met analysts' expectations, and its revenue increased by 7.7% year-over-year.
• Analysts currently maintain an average rating of "Hold" for QIAGEN shares, with a target price averaging $49.69.

Callan Family Office LLC bought a new position in QIAGEN N.V. (NYSE:QGEN - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 6,322 shares of the company's stock, valued at approximately $304,000.

A number of other large investors have also added to or reduced their stakes in the stock. SVB Wealth LLC purchased a new position in shares of QIAGEN during the 1st quarter worth $31,000. Farther Finance Advisors LLC raised its holdings in QIAGEN by 400.5% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company's stock worth $51,000 after purchasing an additional 849 shares during the period. Hilltop National Bank purchased a new position in QIAGEN during the second quarter valued at $66,000. ANTIPODES PARTNERS Ltd purchased a new position in QIAGEN during the first quarter valued at $94,000. Finally, GAMMA Investing LLC grew its holdings in QIAGEN by 93.9% during the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after purchasing an additional 1,425 shares during the period. Institutional investors own 70.00% of the company's stock.

QIAGEN Trading Up 1.2%

QGEN stock opened at $48.10 on Friday. QIAGEN N.V. has a 12 month low of $37.63 and a 12 month high of $51.88. The firm's 50-day moving average is $47.00 and its 200 day moving average is $45.71. The company has a market capitalization of $10.69 billion, a PE ratio of 28.42, a P/E/G ratio of 2.50 and a beta of 0.66. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.61 and a quick ratio of 1.35.

QIAGEN (NYSE:QGEN - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting the consensus estimate of $0.60. The firm had revenue of $533.54 million during the quarter, compared to the consensus estimate of $523.97 million. QIAGEN had a return on equity of 14.77% and a net margin of 18.30%.The firm's quarterly revenue was up 7.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.55 earnings per share. QIAGEN has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, research analysts anticipate that QIAGEN N.V. will post 2.26 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Cowen reiterated a "hold" rating on shares of QIAGEN in a research note on Thursday, August 7th. Barclays set a $53.00 target price on QIAGEN and gave the stock an "overweight" rating in a research report on Thursday, October 2nd. Wall Street Zen cut QIAGEN from a "buy" rating to a "hold" rating in a report on Saturday, October 11th. Bank of America increased their price objective on shares of QIAGEN from $50.00 to $53.00 and gave the company a "buy" rating in a report on Thursday, June 26th. Finally, Weiss Ratings reissued a "hold (c+)" rating on shares of QIAGEN in a report on Wednesday, October 8th. Three analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, QIAGEN currently has an average rating of "Hold" and an average price target of $49.69.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for QIAGEN N.V. (NYSE:QGEN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.